论文部分内容阅读
溃疡性结肠炎的病因尚不明确,但可能有免疫机制参与,其急性恶化过程可能通过Ⅰ型过敏反应所致。鉴于色甘酸二钠治疗过敏性哮喘可阻断其速发的过敏反应,因此作者试用色甘酸二钠对12例溃疡性结肠炎患者以双盲交叉对照法进行临床试验。其中男、女各6例,年龄17～69岁。分为二组,A组7例,先用安慰剂6个月,再换用色甘氨酸二钠6个月;B组5例,先用色甘酸二钠6个月,后换用安慰剂6个月。色甘酸二钠的剂量,最初2周为每次200毫克,每日2次;第3、4周为每次400毫克,每日2次;以后则每次500毫克,每日4次。病人原先使用的柳氮磺胺吡啶(Sulphasalazine)仍继续使用,但不再使用皮质激素或硫唑嘌呤。
The etiology of ulcerative colitis is not clear, but may have immune mechanisms involved, the process of its acute deterioration may be caused by type Ⅰ allergic reactions. Since cromolyn disodium treatment of allergic asthma can block its immediate onset of anaphylactic reactions, the authors tested cromolyn disodium in 12 patients with ulcerative colitis by double-blind cross-over control clinical trial. Including 6 males and 6 females, aged 17 to 69 years old. Divided into two groups, A group of 7 patients, first placebo for 6 months, and then replaced with chromogenic glycine disodium for 6 months; B group of 5 patients, first with cromolyn disodium 6 months, then placebo 6 Months. Disodium cromoglycate dose, the first two weeks for each 200 mg, 2 times a day; 3,4 weeks for each 400 mg, 2 times a day; after each 500 mg, 4 times a day. The patient’s original Sulphasalazine continued to be used, but corticosteroids or azathioprine were no longer used.